This work is licensed under a Creative Commons Attribution 4.0 International License.
Sequence 31 from Patent US 20200079827
General Information
DRACP ID DRACP01508
Peptide Name Sequence 31 from Patent US 20200079827
Sequence LKKWLKKVLGLKGGLWGKVTSVIK
Sequence Length 24
UniProt ID Not available
PubChem CID Not available
Origin Synthetic construct
Type Synthetic peptide
Classification
Active ACP
Activity Information
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antimicrobial
Structure Information
Helicity Not available
Linear/Cyclic Not available
Disulfide/Other Bond Not available
N-terminal Modification Not available
C-terminal Modification Not available
Other Modification None
Chiral L
Physicochemical Information
Formula C130H223N33O27
Absent amino acids ACDEFHMNPQRY
Common amino acids K
Mass 309085
Pl 11.58
Basic residues 7
Acidic residues 0
Hydrophobic residues 11
Net charge 7
Boman Index 524
Hydrophobicity 16.25
Aliphatic Index 133.75
Half Life
Mammalian: 5.5 hour
Yeast: 3 min
E.coli: 2 min
Extinction Coefficient cystines 11000
Absorbance 280nm 478.26
Polar residues 6
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US 2020/0079827 A1
Patent Title Novel Antimicrobial And Anti-cancer Therapy
Other Iinformation Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status: Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022
Other Published ID WO2018094403A1 CN109996554A EP3541405A1 EP3541405A4
This work is licensed under a Creative Commons Attribution 4.0 International License.